1 / 6

- Confidential -

- Confidential -. Eagle Overview. Specialty pharmaceutical company focused on applying several in-licensed technologies to reformulate and improve injectable products

fleur-glass
Download Presentation

- Confidential -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. - Confidential -

  2. Eagle Overview • Specialty pharmaceutical company focused on applying several in-licensed technologies to reformulate and improve injectable products • Eagle evaluates all marketed injectable products. Every product, regardless of how great it may be, can be improved. Eagle’s goal is to improve as many drugs as possible • Eagle’s core competency is linking product selection and market need with the right timing, patent strategy and innovative technology to create a high value, de-risked pipeline • Improvements are targeted towards safety, ease of use, and for optimizing patient benefits through dosing convenience 2 EAGLE CONFIDENTIAL INFORMATION

  3. Eagle Overview • Eagle has developed a well-established pipeline that provides leadership opportunity in the worldwide injectable market • 4 products launching in 2011-2012 with branded market value of ~$800 million • 7 potential launches with shared exclusivity representing ~$4B in innovator brand sales at time of launch • 27 products in pipeline; 19 near term products in development with ~$7B-$8B in US innovator sales (at time of launch) • 8 products in oncology, 3 in critical care, 3 in anti-infectives, 2 in diabetes, 2 in anesthesia, 1 antipsychotic, and 8 TBD • Eagle has 7 product-specific patents allowed / issued and an additional 11 patents filed for Eagle's proprietary and unique formulations. Many additional patents cover platform technologies used in our products • Backed by leading institutional investors including ProQuest Investments, GE Capital, Jennison, and Deerfield 3 EAGLE CONFIDENTIAL INFORMATION

  4. Product Strategy Eagle is dedicated to solving problems of currently available injectable products: • Reducing the number of injections required for treatment • Reducing the number of days required for administration of chemotherapy drugs • Eliminating drug components that create significant negative side effects in patients • Creating long acting formulations, thereby extending the duration of efficacy • Eliminating the need to reconstitute cytotoxic and critical care products • Changing from intravenous to subcutaneous injections (less time in infusion chair) • Creating IV versions of oral medications 4 EAGLE CONFIDENTIAL INFORMATION

  5. Eagle’s Value Drivers • People, Know-how, Early mover • Extraordinary growth rate: high margin, low cost-low risk business model • Broad portfolio of high volume specialty products • Low risk R&D/ inexpensive development costs • 3 NDAs filed, in-house capability to file multiple NDA’s annually • 505(b)(2) NDA’s or sNDA’s minimize development and approval times • De-risked pipeline: formulation data on first 14 products • The 505(b)(2) approval time is approximately half that of an ANDA • Provides the ability to become the leader in the generic injectable market place • Platform to build a leading lifecycle management company with large number of line extensions and specialty injectable products 5 EAGLE CONFIDENTIAL INFORMATION

  6. Headcount by Function 6 EAGLE CONFIDENTIAL INFORMATION

More Related